Interferon and myeloproliferative neoplasms: Evolving therapeutic approaches

Alok Swaroop, Diana Saleiro, Leonidas C. Platanias*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Interferons (IFNs) are a diverse group of cytokines whose potent antitumor effects have piqued the interest of scientists for decades. Some of the most sustained clinical accomplishments have been in the field of myeloproliferative neoplasms (MPNs). Here, we discuss how both historical and novel breakthroughs in our understanding of IFN function may lead to more effective therapies for MPNs. The particular relevance and importance of modulating the novel IFN-regulated ULK1 pathway to optimize IFN responses is highlighted.

Original languageEnglish (US)
Article number2200203
Issue number3
StatePublished - Mar 2023


  • JAK2
  • cytokine
  • essential thrombocytosis
  • interferons
  • myeloproliferative neoplasms
  • polycythemia vera

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Interferon and myeloproliferative neoplasms: Evolving therapeutic approaches'. Together they form a unique fingerprint.

Cite this